IO Biotech Inc. is a clinical-stage biopharmaceutical company headquartered in Copenhagen, Denmark. The company was founded in 2014 and is focused on developing novel immune-modulating cancer vaccines.
IO Biotech's T-win® vaccine platform is designed to stimulate the immune system to attack tumor cells. The platform consists of two components: a tumor-targeting vaccine and a checkpoint inhibitor vaccine. The tumor-targeting vaccine helps the immune system recognize and attack tumor cells. The checkpoint inhibitor vaccine helps the immune system overcome the defenses of tumor cells.
IO Biotech is currently developing a number of T-win® vaccine candidates for the treatment of different types of cancer, including melanoma, lung cancer, and colorectal cancer. The company's lead product candidate, IO102-IO103, is currently in Phase 3 clinical development for the treatment of melanoma.
IO Biotech has a strong team of experienced scientists and executives with a proven track record in the biotechnology industry. The company has raised over $100 million in funding and has a number of strategic partnerships with leading pharmaceutical companies.
IO Biotech is committed to developing innovative cancer vaccines that improve the lives of patients. The company is advancing its pipeline through a combination of in-house research and development and strategic partnerships. IO Biotech is also committed to providing patients with access to its vaccines through a variety of commercialization strategies.